I added stock and bond analysis to my IT consulting business at the request of a small cap investment specialist in 2002. For my own account I invest mainly in technology and biotechnology stocks, but occasionally I invest in industrial, retail and other stocks. My technology and investment web site is openicon.com. I still enjoy IT consulting and always have some sort of R&D project going on.
I have worked in the technology sector for over 4 years. This included working with industry stalwarts like IBM. I have done my MBA in finance and have been covering various blue chip stocks for the past 3 years. Having hands on knowledge in the technology sector has helped me gain valuable insights about the ups and downs of this sector and predict winners and losers more accurately.
Editor for The Biotech Forum, the #2 subscribed to Marketplace investment service offered through SeekingAlpha. Top 5% ranked analyst (TipRanks) 2013 through first half of 2015. Daily contributor for Real Money Pro. Hedge fund manager from 2008 to 2011. Previously technology executive at Fortune 100 firm for a decade.
Please go to biotechforumsa.com for more on the Biotech Forum service available through SeekingAlpha. For Free Investment Reports on a variety of topics go to bretjenseninvests.com
I'm a chartered accountant by profession, hailing from India, who is also pursuing CFA. I look for investments that generate strong value in the long run, and also help investors avoid pitfalls through my analysis.
I come from a background of Electrical Engineering. I enjoyed the creativity of working in the high-tech industry for 24 years, in design and managerial positions. In 2013 I decided to take a few years off from high-tech work, and concentrate on other areas of interest, including investing and stock analysis. I mostly invest in technology, and biotech, which I believe is the next revolution that is already underway, like computers were 20-50 years ago.
Contributors: Scott Tzu, Parke Shall, Thom Lachenmann
(contributors write under pen names for anonymity purposes)
Please read Seeking Alpha's Policy on Anonymous Contributors to familiarize yourself with the site's terms and conditions relating to anonymous authors.
I am an undergrad finance student with a heavy math and analytical background. I usually prefer to invest cheaper, undervalued stocks that I deem have high long-term growth potential after doing much research within the market and specific company. Generally, I stick to areas of interest and knowledge which for me reflects the sports, gaming, and tech industries. All the thoughts reflected in my articles are merely my own personal investment strategies and tips.
Wall Street Breakfast, Seeking Alpha's flagship daily business news summary, is a one-page summary that gives you a rapid overview of the day's key financial news. It's designed for easy readability on the site or by email (including on mobile devices), and is published before 7:00 AM ET every market day.
Wall Street Breakfast readership of over 900,000 includes many from the investment-banking and fund-management industries.
Sign up here to receive the Wall Street Breakfast in your inbox every business day: http://seekingalpha.com/account/email_preferences
Patrick Young is an independent investor. He previously worked in Upstream R&D for ExxonMobil. He has a M.S. in Geology focused on igneous petrology and geochemistry, and is currently working towards a Ph.D. in the same at Yale University. He has wide interests in technology, particularly energy infrastructure.
Alex Cho is a top contributor on Seeking Alpha in both the long ideas and technology section of the website. Alex Cho's articles have been featured on The Motley Fool, The Street, and Benzinga. Alex Cho has been featured on ValueWalk's throwback Thursday for his analysis on Apple. Furthermore, Alex Cho's financial expertise ranks him in the top 100 on TipRanks, and his recommendations have a 80% success rate according to Tip Ranks.
To reach out to him for business opportunities, to share ideas, guest writing opportunities, consulting opportunities e-mail him at firstname.lastname@example.org
The resource referenced below tends to be inaccurate, though it is the only known external site that tracks the performance of stocks written about through Seeking Alpha (when using the S&P 500 as a benchmark). Also, staff responsible for reviewing submissions here may be prohibited from trading, and could easily lack the abilities necessary to interpret financial markets:
Important information follows, please click the link below to review it all:
Work presented may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not historical facts but instead represent only the author's belief regarding future events, many of which, by their nature, are inherently uncertain and outside his control. Except for the author's obligation to disclose material information, the author is not under any obligation (and expressly disclaims any obligation) to update or alter any projections, goals, assumptions, or other statements, whether written or oral, that may be made from time to time, whether as a result of new information, future events or otherwise.
No content within the author's work is a recommendation that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person or purpose. The author is not advising you personally concerning the nature, potential, value or suitability of any particular security, portfolio of securities, transaction, investment strategy or other matter. To the extent that any of the content of this article may be deemed to be investment advice or recommendations in connection with a particular security, such information is impersonal and not tailored to specific investment needs. The author is not an investment advisor and is not offering investment advice. You understand that an investment in any security is subject to a number of risks, and that discussions of any security published will not contain a list or description of relevant risk factors. Some of the stocks about which the author has written and writes about have a low market capitalization and/or insufficient public float. Such stocks are subject to more risk than stocks of larger companies, including greater volatility, lower liquidity and less publicly available information. Any information in the author's work deemed by you to be recommendations may have an effect on their stock prices.
The author's publications are not intended to provide tax, legal, insurance or investment advice, and nothing presented in the author's work should be construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security by Seeking Alpha or any third party. You alone are solely responsible for determining whether any investment, security or strategy, or any other product or service, is appropriate or suitable for you based on your investment objectives and personal and financial situation. You should consult an attorney or tax professional regarding your specific legal or tax situation.
All information in this report is provided "as is" without warranty, expressed or implied, or representations of any kind to the fullest extent permissible under applicable law, the author will not be liable for the quality, accuracy, completeness, reliability, or timeliness of this information, or for any direct, consequential, incidental, special or punitive damages that may arise out of use of this information by you or anyone else, including but not limited to lost profits, loss of opportunities, trading losses, and damage that may result from any inaccuracy or incompleteness of this information to the fullest extent permitted by law. The author denies liability to you or anyone else under any tort, contract, negligence, strict liability, products liability, or other theory with respect to presentation of information.
The information, opinions, data, quantitative and qualitative statements communicated have been obtained from sources believed to be reliable but have not been independently verified and are not guaranteed as to accuracy nor does it purport to be a complete analysis of every material fact regarding the company, industry, or security. The information, opinions, or recommendations are solely for informational purposes and are only valid as of the date appearing on the report and are subject to change without notice. You recognize that performance data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that such calculations are not guaranteed by these sources, the information providers, or any other person or entity, and may not be complete.
The author writes about and invests in high risk companies, some of which succeed, and some of which go out of business completely, rendering securities, including bonds, preferred stock, common stock, options and other financial derivatives valueless.
The author does not intend to receive any inside information from any of the companies written about.
Investors are encouraged to read investment information available at the websites of the SEC at http://www.sec.gov and FINRA at http://www.finra.org.
Prescient Investment Analysis is a person. BA, Boston College, Philosophy.
I hold a PhD in the field of epidemiology a masters degree in public health. My undergraduate training is in policy, economics and the sciences. I have utilized my training in employment with government, academia, private industry and to further analyze the fundamentals and technicals of all manner of companies in different sectors. Specifically, I like to trade growth companies, REITS, biotechnology/ pharmaceuticals, precious metals, blue chips and small-cap companies.
Each market day I get up at 530 am and begin working/analyzing data before my day job. I focus much on current events, earnings, and developments. I also work after market hours to cover after hours developments or interesting action during the day. I aim to conduct 2 analysis per business day, which helps me stay focused on my own finances.
I have been investing for about 10 years. I also enjoy trading short expiration options, and investing in stocks with 3-20 year horizons. I enjoy writing with Seeking Alpha to share my opinion and analyses. I am a large believer in the crowd source model championed by Seeking Alpha and believe every ounce of analysis and opinion should be considered when you invest your personal finances.
Lowenthal Capital Partners is operated by Trevor Lowenthal. Trevor graduated with a BA in Political Science from University of California, Davis with Summa Cum Laude distinction. Trevor is finishing his J.D. at the University of Colorado Law School.
Grant Zeng has over 10 years of professional experience in equity research and analysis. Grant joined Zacks Investment Research Inc. in March 2006, and currently is a senior equity analyst covering biotech/pharma industry. Before joining Zacks, Grant worked for TheStreet.com as a biotech analyst from 2005-2006. From Sept 2001 to December 2003, Grant worked for China Pacific Insurance Co. as an senior equity/fund analyst. Grant was a healthcare equity analyst with Young & Partners, LLC from Aug 2000 to September 2001. Grant had also teaching and researching experience in pharmaceutical science.
Grant Zeng obtained his MBA with a major in Finance in 2000 from McMaster University, Canada. He also holds a Master of Science in Biochemistry from the University of Western Ontario, Canada; Master of Pharmacology and Bachelor of Medicine from Second Military Medical University, China.
Grant Zeng is a Chartered Financial Analyst (CFA) charter holder.
I'm a business graduate with an interest in discovering and writing about healthy investments, which are primarily focused on the healthcare sector.
The stock exchange is a fascination for me and I love to write about any aspect of it.
I'm 32, invest in the light of the Austrian economic tradition, which in today's environment means mostly precious metals and mining stocks using cycles and sentiment as timing mechanisms. ETF's, options, I also own some physical. I've been doing this independently for 3 years. I reserve a small chunk of my portfolio for speculating in biotech and technology where I believe appropriate.
I have a Bachelors Degree in Business Administration and have started up a website with the top 25 biotech stocks. I have been investing in biotech stocks for the last five years, and have done very well. My investing centers around being in long term in biotech stocks, because of the long term value potential. I like the risks in the biotech sector, along with the huge rewards.
I am a physician and vitamin D expert. I am a graduate of the University of North Carolina School of Medicine. In my 35 year career in medicine, I have practiced emergency medicine, general practice and psychiatry.
In 2003, I established the Vitamin D Council, a non-profit dedicated to educating the public and health professionals about vitamin D. I frequently speak about vitamin D and have spoken at the annual meeting of the American Association for the Advancement of Science. I recently served as a "visiting professor" for Marshall University School of Medicine's 25th Annual Research Day.
I have been studying, writing and lecturing about vitamin D for more than 12 years. The Vitamin D Council's website gets over 2.5 million users per year. If you Google my name, "John Cannell", you will get over 60,000 hits, almost all about vitamin D. If you search for "Cannell JJ" on Google Scholar, you will see I have written more than a dozen peer-reviewed scientific articles about vitamin D. Three of my scientific articles (two about influenza and vitamin D and one about autism and vitamin D) are the most cited articles in the history of their respective journals.
I have been occasionally investing, as my personal time and money permit, via long positions over the course of 10 years. I don't work for a brokerage firm, and I'm not a professional trader. My interest has been predominantly within the biotechnology and energy sectors.
I'm a CPA licensed in Maryland. I have Bachelor degrees in both Accounting and Finance.
Stock Twits - http://stocktwits.com/Bio_Bull
Twitter - https://twitter.com/Bio_Bull_SA
Owner and operator of: www.biostockselite.com Have over 15 years of investment experience and interest is dedicated to small cap biotech stocks. Articles submitted to SeekingAlpha will also be posted to my aforementioned site.
Chris DeMuth Jr. is the founder of Rangeley Capital LLC. Rangeley is an investment firm that focuses on event driven, value-oriented investment opportunities. Rangeley Capital and his value investing forum, Sifting the World (StW), search the world for misplaced bets. Rangeley exploits them for its investors and then Mr. DeMuth writes about them on StW.
Awarded a 2015 "Top 50 Financial Blogger" by TipRanks.com
- Ranked #44 out of 4,408 bloggers (#106 out of 8,174 overall experts) as of 8/18/15
- Follow my ongoing coverage on TerraVia (TVIA): http://seekingalpha.com/articles?filters=tvia,kevin-quon
The Last Financier is an independent investor concerned with not only preserving his wealth, but also growing invested capital. He strikes a balance between income-yielding investments, and speculative equities to enhance his portfolio’s alpha. He follows macro trends and delves in misunderstood situations.